Analysts Raise Price Targets for Moody's and Centene on Revised Valuations

Key Facts

In a move reflecting a comprehensive review of valuation models within the financial services and healthcare sectors, analysts have updated their price targets for Moody's and Centene. BMO Capital raised its price target for Moody's (MCO) to $515 while maintaining a Market Perform rating, while Cantor Fitzgerald increased its target for Centene (CNC) from $60 to $75, maintaining an Overweight recommendation. These revisions are based on updated assessments showing Moody's strong financial scores despite recent insider selling, and Centene's significant undervaluation relative to its intrinsic GF Value.

These positive outlooks arrive as investors monitor peer performance; recent earnings from S&P Global (SPGI), a direct competitor to Moody's, showed robust growth in credit ratings driven by increased bond issuance per quarterly earnings reports. For Centene, the new $75 target represents a notable premium over current market prices, aligning with analyst trends favoring undervalued managed care organizations like UnitedHealth Group (UNH), which reported stable performance in the latest quarter per market data.

Regarding price levels, Moody's (trading as 0K36.L) stood at $497.08 at the close of July 6, 2026, while Centene (CNC) was priced at $66.05 as of the same date. Traders should monitor upcoming macroeconomic catalysts, as U.S. inflation and employment data could influence broader market sentiment and borrowing costs, directly impacting the bond issuance activity critical to Moody's and the operational costs for healthcare providers like Centene.